- Home
- AXL vs PHAT Comparison
AXL vs PHAT Comparison
Compare AXL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXL | PHAT |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 795.3M | 942.6M |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AXL | PHAT |
|---|---|---|
| Price | $6.37 | $16.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $7.06 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 2.6M | 911.0K |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $5,833,600,000.00 | $147,190,000.00 |
| Revenue This Year | N/A | $218.59 |
| Revenue Next Year | $0.71 | $84.38 |
| P/E Ratio | $19.14 | ★ N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $3.00 | $2.21 |
| 52 Week High | $6.82 | $18.28 |
Technical Indicators
Market Signals| Indicator | AXL | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 49.88 | 66.14 |
| Support Level | $6.27 | $14.24 |
| Resistance Level | $6.82 | $16.45 |
| Average True Range (ATR) | 0.23 | 0.89 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 46.54 | 68.38 |
Price Performance
Historical ComparisonAbout AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.